Corcept Therapeutics Incorporated (NASDAQ:CORT) said on Thursday that it presented results from its Phase 2 DAZALS study of ...

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of ...

Prescribed use of anti-anxiety drugs, hypnotics and sedatives, or antidepressants was tied to a higher future risk of ...

Nothing is clicking for a Rangers offense that is so bad, it has made its great pitching staff nearly irrelevant. | Opinion ...

The donation will establish the Lois Pope Neuroscience Research Fund and will add Lorraine's name to the Lois Pope Laboratory ...

Corcept Therapeutics has tried to cast its recent phase 2 amyotrophic lateral sclerosis (ALS) failure in a more flattering ...

Brainstorm tapped Minaris to manufacture NurOwn for its upcoming Phase 3b clinical trial testing the treatment for ALS.

UC Irvine researchers conducted a study to better understand the molecular basis of amyotrophic lateral sclerosis (ALS), a ...

Richter died on Monday, June 2, after a brief illness. A celebration of her life and legacy will be celebrated at a future date.

Corcept Therapeutics' dazucorilant failed the primary ALS trial goal but showed improved survival outcomes and a safe profile ...

Experimental drug Ulefnersen shows potential in halting and even reversing symptoms in patients with FUS- Amyotrophic lateral sclerosis (ALS) mutation One patient regained full motor function ...

Analysts at Truist Securities called the mid-stage data a "mixed bag," also flagging gastrointestinal adverse events. However ...